Skip to content
  • Home
  • How We Work
    • The Impact of Autophagy in Health and Disease
    • Biophagy’s Business Model
    • Biophagy’s Proprietary Drug Development
    • Cell Watchᵀᴹ
  • Business Development
  • Background & News
  • Team
  • Contact
Previous Next

Biophagy is awarded a New Mexico Small Business Assistance (NMSBA) leverage grant with Sandia National Laboratories to lead a team of four companies (including Avisa Pharma, PureInfo Discovery, and Omphalos Biosciences) to investigate binding dynamics of several proprietary autophagy stimulants on cytoskeleton and lysosome movement. They will also study compound enhancement of antibiotic killing using M. bovis, in mouse macrophages. This is a surrogate assay for tuberculosis.

By jordan|2022-03-22T20:38:46+00:00February 1, 2022|2018-announcements|0 Comments

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: jordan

Related Posts

  • Biophagy initiates a collaboration with Dr. Karin High, UNM, to study its proprietary compounds in chronic neuropathic pain, in vivo.

    Biophagy initiates a collaboration with Dr. Karin High, UNM, to study its proprietary compounds in chronic neuropathic pain, in vivo.

Leave A Comment Cancel reply

Copyright 2022 | All Rights Reserved | Website Design and Development by Ingenuity Software Labs
FacebookTwitterInstagramPinterest
Page load link
Go to Top